Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

This comparative effectiveness research compares survival end points and response rates among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib and cabazitaxel using results from 2 phase 3 randomized clinical trials.

Detalles Bibliográficos
Autores principales: Wallis, Christopher J. D., Klaassen, Zachary, Jackson, William C., Dess, Robert T., Reichert, Zachery R., Sun, Yilun, Spratt, Daniel E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144926/
https://www.ncbi.nlm.nih.gov/pubmed/34028551
http://dx.doi.org/10.1001/jamanetworkopen.2021.10950
_version_ 1783697060946509824
author Wallis, Christopher J. D.
Klaassen, Zachary
Jackson, William C.
Dess, Robert T.
Reichert, Zachery R.
Sun, Yilun
Spratt, Daniel E.
author_facet Wallis, Christopher J. D.
Klaassen, Zachary
Jackson, William C.
Dess, Robert T.
Reichert, Zachery R.
Sun, Yilun
Spratt, Daniel E.
author_sort Wallis, Christopher J. D.
collection PubMed
description This comparative effectiveness research compares survival end points and response rates among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib and cabazitaxel using results from 2 phase 3 randomized clinical trials.
format Online
Article
Text
id pubmed-8144926
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-81449262021-06-09 Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Wallis, Christopher J. D. Klaassen, Zachary Jackson, William C. Dess, Robert T. Reichert, Zachery R. Sun, Yilun Spratt, Daniel E. JAMA Netw Open Research Letter This comparative effectiveness research compares survival end points and response rates among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib and cabazitaxel using results from 2 phase 3 randomized clinical trials. American Medical Association 2021-05-24 /pmc/articles/PMC8144926/ /pubmed/34028551 http://dx.doi.org/10.1001/jamanetworkopen.2021.10950 Text en Copyright 2021 Wallis CJD et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Wallis, Christopher J. D.
Klaassen, Zachary
Jackson, William C.
Dess, Robert T.
Reichert, Zachery R.
Sun, Yilun
Spratt, Daniel E.
Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
title Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
title_full Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
title_fullStr Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
title_full_unstemmed Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
title_short Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
title_sort olaparib vs cabazitaxel in metastatic castration-resistant prostate cancer
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144926/
https://www.ncbi.nlm.nih.gov/pubmed/34028551
http://dx.doi.org/10.1001/jamanetworkopen.2021.10950
work_keys_str_mv AT wallischristopherjd olaparibvscabazitaxelinmetastaticcastrationresistantprostatecancer
AT klaassenzachary olaparibvscabazitaxelinmetastaticcastrationresistantprostatecancer
AT jacksonwilliamc olaparibvscabazitaxelinmetastaticcastrationresistantprostatecancer
AT dessrobertt olaparibvscabazitaxelinmetastaticcastrationresistantprostatecancer
AT reichertzacheryr olaparibvscabazitaxelinmetastaticcastrationresistantprostatecancer
AT sunyilun olaparibvscabazitaxelinmetastaticcastrationresistantprostatecancer
AT sprattdaniele olaparibvscabazitaxelinmetastaticcastrationresistantprostatecancer

Ejemplares similares